Boston Scientific saw a profit boom in the third quarter of the year, leading the company to increase its full-year forecast for 2025. The company is now projecting revenue growth of 20% for the ...
Boston Scientific’s BSX Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace ...
Boston Scientific has lifted its fiscal year 2025 (FY25) profit outlook to between $3.02 and $3.04 per share amid continued strong performance in its third quarter (Q3), largely driven by growth in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results